莫他赛珠单抗。
Motavizumab.
机构信息
Department of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, MA, USA.
出版信息
MAbs. 2009 Sep-Oct;1(5):439-42. doi: 10.4161/mabs.1.5.9496. Epub 2009 Sep 10.
Abstract
Motavizumab (MEDI-524, Numax) is a second generation monoclonal antibody (mAb) derived from palivizumab (Synagis) using affinity maturation techniques. Motavizumab is currently undergoing US Food and Drug Administration review as a treatment for respiratory syncytial virus (RSV) prophylaxis. It has been evaluated in large-scale clinical studies, and has demonstrated efficacy in reducing the disease burden of RSV in high-risk infant populations.
摘要
莫达珠单抗（MEDI-524，Numax）是第二代单克隆抗体（mAb），使用亲和力成熟技术从帕利珠单抗（Synagis）衍生而来。莫达珠单抗目前正在接受美国食品和药物管理局的审查，作为治疗呼吸道合胞病毒（RSV）预防的药物。它已经在大规模临床研究中进行了评估，并证明了在降低高危婴儿人群 RSV 疾病负担方面的疗效。
相似文献
1
Motavizumab.莫他赛珠单抗。
MAbs. 2009 Sep-Oct;1(5):439-42. doi: 10.4161/mabs.1.5.9496. Epub 2009 Sep 10.
2
Safety and antiviral activity of motavizumab, a respiratory syncytial virus (RSV)-specific humanized monoclonal antibody, when administered to RSV-infected children.莫替沙韦单抗（一种针对呼吸道合胞病毒[RSV]的人源化单克隆抗体）在 RSV 感染儿童中的安全性和抗病毒活性。
Pediatr Infect Dis J. 2009 Sep;28(9):835-7. doi: 10.1097/INF.0b013e3181a165e4.
3
A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season.一项评估莫替沙韦单抗和帕利珠单抗联合用药用于呼吸道合胞病毒（RSV）预防的 2 期、随机、双盲安全性和药代动力学研究。
BMC Pediatr. 2010 Jun 3;10:38. doi: 10.1186/1471-2431-10-38.
4
5
Systematic Review of the Efficacy and Safety of RSV-Specific Monoclonal Antibodies and Antivirals in Development.系统评价 RSV 特异性单克隆抗体和在研抗病毒药物的疗效和安全性。
Rev Med Virol. 2024 Sep;34(5):e2576. doi: 10.1002/rmv.2576.
6
Safety and immunogenicity of palivizumab (Synagis) administered for two seasons.帕利珠单抗（赛诺菲）连续两个季节给药的安全性和免疫原性。
Pediatr Infect Dis J. 2005 Nov;24(11):1021-3. doi: 10.1097/01.inf.0000183938.33484.bd.
7
Prevention of respiratory syncytial virus (RSV) infection: RSV immune globulin intravenous and palivizumab. (American Academy of Pediatrics).
Pediatr Ann. 1999 Aug;28(8):507-14. doi: 10.3928/0090-4481-19990801-08.
8
Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab.对呼吸道合胞病毒临床前及临床变体的分析，这些变体对单克隆抗体帕利珠单抗和/或莫他珠单抗的中和作用具有抗性。
J Infect Dis. 2011 Mar 1;203(5):674-82. doi: 10.1093/infdis/jiq100. Epub 2011 Jan 5.
9
Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.用于降低儿童呼吸道合胞病毒感染风险的单克隆抗体。
Cochrane Database Syst Rev. 2013 Apr 30(4):CD006602. doi: 10.1002/14651858.CD006602.pub4.
10
Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.莫他维izumab的研发，一种用于预防上、下呼吸道呼吸道合胞病毒感染的超高效抗体。
J Mol Biol. 2007 May 4;368(3):652-65. doi: 10.1016/j.jmb.2007.02.024. Epub 2007 Feb 20.
引用本文的文献
1
The recent landscape of RSV vaccine research.呼吸道合胞病毒疫苗研究的最新概况。
Ther Adv Vaccines Immunother. 2025 Jan 10;13:25151355241310601. doi: 10.1177/25151355241310601. eCollection 2025.
2
Respiratory Syncytial Virus: A WAidid Consensus Document on New Preventive Options.呼吸道合胞病毒：关于新预防方案的瓦迪德共识文件
Vaccines (Basel). 2024 Nov 25;12(12):1317. doi: 10.3390/vaccines12121317.
3
Vaccine and therapeutic agents against the respiratory syncytial virus: resolved and unresolved issue.抗呼吸道合胞病毒的疫苗和治疗药物：已解决和未解决的问题
MedComm (2020). 2024 Nov 21;5(12):e70016. doi: 10.1002/mco2.70016. eCollection 2024 Dec.
4
SYNBIP 2.0: epitopes mapping, sequence expansion and scaffolds discovery for synthetic binding protein innovation.SYNBIP 2.0：用于合成结合蛋白创新的表位映射、序列扩展和支架发现
Nucleic Acids Res. 2025 Jan 6;53(D1):D595-D603. doi: 10.1093/nar/gkae893.
5
Analysis of Beyfortus (Nirsevimab) Immunization Campaign: Effectiveness, Biases, and ADE Risks in RSV Prevention.Beyfortus（尼塞韦单抗）免疫接种活动分析：呼吸道合胞病毒预防中的有效性、偏倚和不良事件风险
Curr Issues Mol Biol. 2024 Sep 18;46(9):10369-10395. doi: 10.3390/cimb46090617.
6
Prevention and Potential Treatment Strategies for Respiratory Syncytial Virus.呼吸道合胞病毒的预防和潜在治疗策略。
Molecules. 2024 Jan 25;29(3):598. doi: 10.3390/molecules29030598.
7
Clinical research on RSV prevention in children and pregnant women: progress and perspectives.儿童和孕妇呼吸道合胞病毒预防的临床研究：进展与展望。
Front Immunol. 2024 Jan 24;14:1329426. doi: 10.3389/fimmu.2023.1329426. eCollection 2023.
8
Innovations in monoclonal antibody-based multipurpose prevention technology (MPT) for the prevention of sexually transmitted infections and unintended pregnancy.基于单克隆抗体的多用途预防技术（MPT）在预防性传播感染和意外怀孕方面的创新。
Front Reprod Health. 2024 Jan 9;5:1337479. doi: 10.3389/frph.2023.1337479. eCollection 2023.
9
HIV-1 neutralizing antibodies elicited in humans by a prefusion-stabilized envelope trimer form a reproducible class targeting fusion peptide.由预融合稳定的包膜三聚体在人体内诱导产生的 HIV-1 中和抗体形成了一个可重复的针对融合肽的类别。
Cell Rep. 2023 Jul 25;42(7):112755. doi: 10.1016/j.celrep.2023.112755. Epub 2023 Jul 11.
10
New Developments and Challenges in Antibody-Based Therapies for the Respiratory Syncytial Virus.呼吸道合胞病毒基于抗体疗法的新进展与挑战
Infect Drug Resist. 2023 Apr 8;16:2061-2074. doi: 10.2147/IDR.S379660. eCollection 2023.
本文引用的文献
1
2
Safety, tolerability, pharmacokinetics, and immunogenicity of motavizumab, a humanized, enhanced-potency monoclonal antibody for the prevention of respiratory syncytial virus infection in at-risk children.莫他维izumab的安全性、耐受性、药代动力学及免疫原性研究，莫他维izumab是一种人源化、高效单克隆抗体，用于预防高危儿童呼吸道合胞病毒感染。
Pediatr Infect Dis J. 2009 Apr;28(4):267-72. doi: 10.1097/INF.0b013e31818ffd03.
3
Immunoprophylaxis of RSV infection: advancing from RSV-IGIV to palivizumab and motavizumab.呼吸道合胞病毒感染的免疫预防：从呼吸道合胞病毒免疫球蛋白静脉注射剂发展到帕利珠单抗和莫他珠单抗。
Curr Top Microbiol Immunol. 2008;317:103-23. doi: 10.1007/978-3-540-72146-8_4.
4
Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.莫他维izumab的研发，一种用于预防上、下呼吸道呼吸道合胞病毒感染的超高效抗体。
J Mol Biol. 2007 May 4;368(3):652-65. doi: 10.1016/j.jmb.2007.02.024. Epub 2007 Feb 20.
5
Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus potency.两种中和抗呼吸道合胞病毒（RSV）单克隆抗体在RSV小鼠模型中的比较效果：时间与效力。
Antimicrob Agents Chemother. 2005 Nov;49(11):4700-7. doi: 10.1128/AAC.49.11.4700-4707.2005.
6
Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization.针对呼吸道合胞病毒的超高效抗体：结合动力学和结合价对病毒中和作用的影响
J Mol Biol. 2005 Jul 1;350(1):126-44. doi: 10.1016/j.jmb.2005.04.049.
7
Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus.一种对呼吸道合胞病毒具有强大体外和体内活性的人源化单克隆抗体（MEDI-493）的研发。
J Infect Dis. 1997 Nov;176(5):1215-24. doi: 10.1086/514115.
8
Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study.雾化吸入利巴韦林治疗呼吸道合胞病毒感染婴儿。一项随机双盲研究。
N Engl J Med. 1983 Jun 16;308(24):1443-7. doi: 10.1056/NEJM198306163082403.
Zotero 插件